|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.26 USD | -0.44% |
|
+5.22% | +3.78% |
| 07-02 | National Health Investors Completes $560 Million Sale of 35 Healthcare Facilities | MT |
| 07-02 | National Healthcare Buys Nursing Facility Real Estate for $560 Million | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.87 | 3.36 | 4.48 | 4.63 | 4.52 | |||||
Return on Total Capital | 3.98 | 3.46 | 4.62 | 4.78 | 4.67 | |||||
Return On Equity % | 7.37 | 4.67 | 10.48 | 10.28 | 9.63 | |||||
Return on Common Equity | 7.41 | 4.78 | 10.74 | 10.52 | 9.83 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 96.08 | 96.49 | 96.41 | 96.67 | 81.04 | |||||
SG&A Margin | 6.51 | 9.08 | 6.19 | 6.49 | 7.79 | |||||
EBITDA Margin % | 89.3 | 76.99 | 77.72 | 77.58 | 72.97 | |||||
EBITA Margin % | 62.09 | 51.56 | 55.88 | 56.29 | 51.63 | |||||
EBIT Margin % | 62.09 | 51.56 | 55.88 | 56.29 | 51.63 | |||||
Income From Continuing Operations Margin % | 37.71 | 23.5 | 41.94 | 40.72 | 37.12 | |||||
Net Income Margin % | 37.66 | 23.82 | 42.34 | 41.12 | 37.48 | |||||
Net Avail. For Common Margin % | 37.66 | 23.82 | 42.32 | 41.08 | 37.43 | |||||
Normalized Net Income Margin | 28.05 | 22.73 | 24.02 | 24.43 | 22.92 | |||||
Levered Free Cash Flow Margin | 36.37 | 69.63 | 59.55 | 50.14 | 51.54 | |||||
Unlevered Free Cash Flow Margin | 45.6 | 78.16 | 69.43 | 59.34 | 60.09 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.1 | 0.1 | 0.13 | 0.13 | 0.14 | |||||
Fixed Assets Turnover | 0.12 | 0.13 | 0.15 | 0.16 | 0.16 | |||||
Receivables Turnover (Average Receivables) | 2.74 | 2.4 | 2.91 | 2.81 | 3.03 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.28 | 2.35 | 0.84 | 0.31 | 0.54 | |||||
Quick Ratio | 2.12 | 1.56 | 0.75 | 0.29 | 0.5 | |||||
Operating Cash Flow to Current Liabilities | 3.27 | 2.85 | 1.24 | 0.51 | 1.12 | |||||
Days Sales Outstanding (Average Receivables) | 133.12 | 151.96 | 125.57 | 130.45 | 120.32 | |||||
Average Days Payable Outstanding | 568 | 728.77 | 832.88 | 872.71 | 159.36 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 81.93 | 88.96 | 89.22 | 82.86 | 75.69 | |||||
Total Debt / Total Capital | 45.03 | 47.08 | 47.15 | 45.31 | 43.08 | |||||
LT Debt/Equity | 81.93 | 88.96 | 83.17 | 59.21 | 67.56 | |||||
Long-Term Debt / Total Capital | 45.03 | 47.08 | 43.95 | 32.38 | 38.46 | |||||
Total Liabilities / Total Assets | 46.56 | 48.56 | 48.8 | 47.02 | 44.94 | |||||
EBIT / Interest Expense | 3.63 | 3.2 | 3.08 | 3.15 | 3.41 | |||||
EBITDA / Interest Expense | 5.22 | 4.78 | 4.28 | 4.35 | 4.83 | |||||
(EBITDA - Capex) / Interest Expense | 5.22 | 4.78 | 4.22 | 4.28 | 4.83 | |||||
Total Debt / EBITDA | 4.69 | 5.35 | 4.56 | 4.41 | 4.21 | |||||
Net Debt / EBITDA | 4.55 | 5.26 | 4.47 | 4.31 | 4.14 | |||||
Total Debt / (EBITDA - Capex) | 4.69 | 5.35 | 4.63 | 4.48 | 4.21 | |||||
Net Debt / (EBITDA - Capex) | 4.55 | 5.26 | 4.54 | 4.38 | 4.14 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -9.94 | -6.19 | 14.93 | 4.74 | 13.02 | |||||
Gross Profit, 1 Yr. Growth % | -10.86 | -5.8 | 14.83 | 5.03 | 8.94 | |||||
EBITDA, 1 Yr. Growth % | -13.05 | -19.14 | 16.03 | 4.55 | 6.31 | |||||
EBITA, 1 Yr. Growth % | -16.89 | -22.14 | 24.57 | 5.5 | 3.67 | |||||
EBIT, 1 Yr. Growth % | -16.89 | -22.14 | 24.57 | 5.5 | 3.67 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -39.58 | -41.5 | 105.16 | 1.68 | 3.04 | |||||
Net Income, 1 Yr. Growth % | -39.61 | -40.61 | 104.29 | 1.72 | 3.04 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -41.06 | -39.34 | 111.16 | 0.15 | -3.51 | |||||
Normalized Net Income, 1 Yr. Growth % | -20.96 | -24.28 | 21.46 | 6.52 | 6.07 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -13.1 | -8.61 | -0.53 | 4.94 | 11.87 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.13 | -17.66 | 9.49 | 4.44 | -8.7 | |||||
Total Assets, 1 Yr. Growth % | -9.02 | -11.68 | -0.76 | 5.06 | 6.98 | |||||
Common Equity, 1 Yr. Growth % | -0.34 | -15.72 | -1.28 | 8.97 | 11.35 | |||||
Tangible Book Value, 1 Yr. Growth % | -0.34 | -15.72 | -1.28 | 8.97 | 11.35 | |||||
Cash From Operations, 1 Yr. Growth % | -9.17 | -12.1 | -0.48 | 12.64 | 13.86 | |||||
Capital Expenditures, 1 Yr. Growth % | -59.49 | - | - | 8.71 | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -58.63 | 79.35 | -1.7 | -11.81 | 15.31 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -53.1 | 60.65 | 2.1 | -10.49 | 12.17 | |||||
Dividend Per Share, 1 Yr. Growth % | -13.78 | -5.33 | 0 | 0 | 1.11 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -3.39 | -8.05 | 3.83 | 9.72 | 8.8 | |||||
Gross Profit, 2 Yr. CAGR % | -4.43 | -8.32 | 4.01 | 9.82 | 6.84 | |||||
EBITDA, 2 Yr. CAGR % | -5.5 | -16.11 | -3.14 | 10.14 | 5.42 | |||||
EBITA, 2 Yr. CAGR % | -8.48 | -19.5 | -1.52 | 14.64 | 4.58 | |||||
EBIT, 2 Yr. CAGR % | -8.48 | -19.5 | -1.52 | 14.64 | 4.58 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -16.46 | -40.55 | 9.55 | 44.43 | 2.36 | |||||
Net Income, 2 Yr. CAGR % | -16.53 | -40.11 | 10.15 | 44.15 | 2.38 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -18.46 | -40.21 | 13.17 | 45.43 | -1.7 | |||||
Normalized Net Income, 2 Yr. CAGR % | -9.79 | -22.46 | -4.1 | 13.74 | 6.29 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -4.85 | -10.89 | -4.66 | 2.17 | 8.35 | |||||
Accounts Receivable, 2 Yr. CAGR % | 5.53 | -8.74 | -5.05 | 6.94 | -2.35 | |||||
Total Assets, 2 Yr. CAGR % | -3.4 | -10.36 | -6.37 | 2.11 | 6.02 | |||||
Common Equity, 2 Yr. CAGR % | 0.32 | -8.35 | -8.78 | 3.72 | 10.15 | |||||
Tangible Book Value, 2 Yr. CAGR % | 0.32 | -8.35 | -8.78 | 3.72 | 10.15 | |||||
Cash From Operations, 2 Yr. CAGR % | -6.45 | -10.65 | -6.47 | 5.88 | 13.25 | |||||
Capital Expenditures, 2 Yr. CAGR % | - | - | 664.75 | - | - | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -25.05 | -13.79 | 32.82 | -6.89 | 0.77 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -21.96 | -13.15 | 28.1 | -4.4 | 0.38 | |||||
Dividend Per Share, 2 Yr. CAGR % | -4.85 | -9.65 | -2.7 | 0 | 0.55 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 0.26 | -4.3 | -0.95 | 4.14 | 10.81 | |||||
Gross Profit, 3 Yr. CAGR % | -0.53 | -4.86 | -1.18 | 4.35 | 4.55 | |||||
EBITDA, 3 Yr. CAGR % | -1.31 | -10.25 | -6.53 | -0.64 | 8.85 | |||||
EBITA, 3 Yr. CAGR % | -3.4 | -13.24 | -6.89 | 0.77 | 10.86 | |||||
EBIT, 3 Yr. CAGR % | -3.4 | -13.24 | -6.89 | 0.77 | 10.86 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -10.14 | -25.82 | -10.16 | 6.86 | 29.05 | |||||
Net Income, 3 Yr. CAGR % | -10.19 | -25.48 | -9.85 | 7.26 | 28.89 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -12.72 | -26.12 | -8.95 | 8.66 | 26.84 | |||||
Normalized Net Income, 3 Yr. CAGR % | -5 | -14.78 | -9.95 | -0.69 | 11.12 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | -0.7 | -6.12 | -7.56 | -1.56 | 5.31 | |||||
Accounts Receivable, 3 Yr. CAGR % | -3.9 | -2.84 | -3.03 | -1.98 | 1.45 | |||||
Total Assets, 3 Yr. CAGR % | 1.06 | -6.24 | -7.27 | -2.71 | 3.71 | |||||
Common Equity, 3 Yr. CAGR % | 2.74 | -5.34 | -6.05 | -3.21 | 6.2 | |||||
Tangible Book Value, 3 Yr. CAGR % | 2.74 | -5.34 | -6.05 | -3.21 | 6.2 | |||||
Cash From Operations, 3 Yr. CAGR % | 0.48 | -8.38 | -7.38 | -0.49 | 8.47 | |||||
Capital Expenditures, 3 Yr. CAGR % | - | - | - | 299.12 | - | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -14.22 | 0.32 | -9.94 | 15.87 | 0.24 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -11.8 | -0.67 | -8.34 | 13.67 | 1.51 | |||||
Dividend Per Share, 3 Yr. CAGR % | -1.67 | -5.01 | -6.54 | -1.81 | 0.37 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 3.73 | 0.01 | 1.69 | 1.08 | 2.84 | |||||
Gross Profit, 5 Yr. CAGR % | 2.9 | -0.7 | 1.28 | 0.76 | -0.8 | |||||
EBITDA, 5 Yr. CAGR % | 3.19 | -4.13 | -2.02 | -2.59 | -1.92 | |||||
EBITA, 5 Yr. CAGR % | 1.98 | -6.19 | -2.62 | -3.01 | -2.46 | |||||
EBIT, 5 Yr. CAGR % | 1.99 | -6.19 | -2.62 | -3.01 | -2.46 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -6.02 | -16.29 | -2.73 | -3.16 | -5.35 | |||||
Net Income, 5 Yr. CAGR % | -5.9 | -16.06 | -2.55 | -2.97 | -5.14 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -8.81 | -17.49 | -3.16 | -3.13 | -6.11 | |||||
Normalized Net Income, 5 Yr. CAGR % | 1.77 | -7.72 | -4.55 | -4.35 | -3.77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 1.42 | -1.51 | -2.3 | -2.89 | -1.5 | |||||
Accounts Receivable, 5 Yr. CAGR % | 3.99 | -3.88 | -4.36 | 0.96 | -2.76 | |||||
Total Assets, 5 Yr. CAGR % | 3.38 | -0.3 | -1.98 | -2.99 | -2.17 | |||||
Common Equity, 5 Yr. CAGR % | 4.5 | -0.8 | -2.04 | -1.82 | 0.12 | |||||
Tangible Book Value, 5 Yr. CAGR % | 4.5 | -0.8 | -2.04 | -1.82 | 0.12 | |||||
Cash From Operations, 5 Yr. CAGR % | 3.61 | -1.32 | -2.36 | -2.92 | 0.38 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -2.32 | 6.63 | 2.21 | -2.63 | -5.63 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -1.35 | 5.85 | 2.43 | -2.18 | -4.63 | |||||
Dividend Per Share, 5 Yr. CAGR % | 1.1 | -1.08 | -2.09 | -3.04 | -3.77 |
- Stock Market
- Stocks
- NHI Stock
- Financials National Health Investors, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















